Premature Infant
1
Pipeline Programs
4
Companies
3
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
4 companies ranked by most advanced pipeline stage
Colorado TherapeuticsCO - Louisville
1 programGenesis Electrical Impedance Tomography (EIT): A Preliminary StudyN/A1 trial
Active Trials
1 program
iRes Warmer with ResusViewN/A1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Autonomous TherapeuticsEpo
GE HealthCareiRes Warmer with ResusView
Colorado TherapeuticsGenesis Electrical Impedance Tomography (EIT): A Preliminary Study
Clinical Trials (3)
Total enrollment: 190 patients across 3 trials
Erythropoietin in Premature Infants to Prevent Encephalopathy
Start: Sep 2015Est. completion: Dec 201658 patients
Phase 2Terminated
Time to Accurate Heart Rate on Neonatal Outcomes
Start: Feb 2021Est. completion: Dec 202142 patients
N/ACompleted
Genesis Electrical Impedance Tomography (EIT): A Preliminary Study
Start: May 2019Est. completion: Nov 202690 patients
N/ARecruiting
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 actively recruiting trials targeting 190 patients
4 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.